Down 52% In 3 Months, Is Moderna Stock a Bargain Buy?
Since the debut of its white-hot coronavirus vaccine, Moderna (NASDAQ: MRNA) has been an insanely good stock to own. If someone had purchased its stock in the middle of March of 2020, their investment would be up more than 534%. Unfortunately, if they'd tried the same investment six months ago, they'd be down by just over 60%.
The secret is that Moderna's business hasn't fundamentally changed, and it's still a company that's capable of developing world-changing medicines. So it's still a stock that could be a great pick for the right portfolio -- and now that it's down from its heights, it might even be selling at a discount. Let's compare its valuation to a few of its peers and figure out if there's a compelling reason to buy.
Image source: Getty Images.
Source Fool.com
